Zobrazeno 1 - 10
of 218
pro vyhledávání: '"B. Osterwalder"'
Autor:
D. Pollyea, L. Gore, J. Gutman, S. G. Eckhardt, N. Hagelstrom, S. Coutre, M. Thirman, J. Byrd, G. Massimini, B. Laffranchi, N. Rejeb, E. Asatiani, A. Milner, O. von Richter, G. Locatelli, J. A. Ogden, B. Osterwalder, R. Meng, L. R. Molife, L. de Mattos-Arruda, A. Hollebecque, S. J. Isakoff, D. Roda, Y. Yan, A. Cervantes, J. C. Soria, J. Mateo, G. Argiles, J. C. Bendell, A. El-Khoueiry, D. J. Jonker, M. B. Sawyer, L. Wong, C. R. Becerra, J. M. Chemidlin, G. Kollia, D. S. A. Nuyten, C. J. Twelves, D. K. Wilkins, A. Anthoney, J. Chappell, W. T. Ng, P. T. Turner, R. Kristeleit, O. Schoenborn-Kellenberger, A. Suder
Publikováno v:
Annals of Oncology. 24:i33-i35
Autor:
P Eisenberg, S. Van Belle, S. Laws, B Osterwalder, H-U Burger, V Moiseyenko, S M O'Reilly, D Melnychuk, E Alba Conejo, T Pienkowski, Stephen P. Ackland, D C Talbot
Publikováno v:
British Journal of Cancer
Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial evaluated the efficacy and safety of capecitabine or paclitaxel in patients with anthracyclin
Autor:
G. T. Budd, B Osterwalder, D Z Chang, R. Ganapathi, Thomas Olencki, Ronald M. Bukowski, David M. Peereboom
Publikováno v:
Cancer Chemotherapy and Pharmacology. 48:493-498
Purpose: The present study was designed to determine the toxicity and maximum tolerated doses of oral intermittent oral capecitabine and subcutaneous (s.c.) rHuIFNα2a in patients with metastatic renal cell carcinoma (RCC). The pharmacokinetics of ca
Publikováno v:
Annals of Oncology. 5:141-146
Summary Background Opioid and spinal monoaminergic agonists have distinct analgesic properties, which may potentiate eachother. Tramadol has both opioid and monoaminergic agonist actions. This initial study compared the analgesic and toxic effects of
Autor:
King, P Hatch, R Bianchi, M Ovsyannikov, R Lupulescu, C Landolt, G Slomski, B Dil, J Guan, D Mi, J Rienks, E Fink, J Lindblad, A Svensson, S Bao, S Balakrishnan, G Iversen, B Osterwalder, J Eberhardt, W Baumberger, F Hofmann
Publikováno v:
Physical Review Letters.
Publikováno v:
Acta Oncologica. 30:731-734
The antiemetic efficacy of cinnarizine was assessed in 17 cancer patients receiving platin-based chemotherapy (cisplatin dose-range 30-160 mg, or carboplatin 270-600 mg) in a randomised, cross-over study. The patients were prophylactically given oral
Autor:
George P. Browman, B. Osterwalder, Richard Klasa, A. Muldal, Elizabeth Eisenhauer, Andrew Belch
Publikováno v:
Annals of Oncology. 6:721-723
Background : Several studies have shown that interferon α as a single agent produces responses in multiple myeloma patients, and may prolong remission duration. In vitro studies of interleukin-2 (rHu-IL-2) in multiple myeloma models indicate that rH
Autor:
B. Osterwalder, Wim H. J. Kruit, S. H. Goey, H. Poliwoda, F. Calabresi, G. Stoter, A. Lindemann, Rolf A. Stahel
Publikováno v:
British Journal of Cancer
Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeat
Publikováno v:
Cancer. 92(7)
Capecitabine is an oral, tumor-targeted fluoropyrimidine carbamate with high activity in metastatic breast carcinoma and in paclitaxel-pretreated metastatic breast carcinoma.The current multicenter, Phase II trial assessed the efficacy and safety of
Autor:
V M, Moiseenko, S M, O'Reilly, D C, Dalbot, S, Van Belle, R J, Gordon, T, Griffin, B, Osterwalder
Publikováno v:
Voprosy onkologii. 46(3)
A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs. Capecitabine and paclitaxel showed comparable effe